Loading...

Rafael Bejar

Title(s)Associate Clinical Professor -, Medicine
SchoolHealth Sciences
Address9500 Gilman Drive #0820
La Jolla CA 92093
Phone858-534-5204
vCardDownload vCard

    Collapse Overview 
    Collapse Overview
    Research Interests
    Our lab is focused on understanding the genetic changes that drive the development and progression of hematologic malignancies like acute myeloid leukemia and myelodysplastic syndromes. Our goal is to translate our discoveries into clinically meaningful improvements in how we care for patients with these disorders.

    Our prior work helped characterize the range of genetic alterations that exist in patients with myelodysplastic syndromes (MDS). We studied bone marrow sample from over 400 patients with these disorders and examined them for mutations in over 20 recurrently mutated genes. We learned about the relative frequency of these mutations, how they can overlap with each other, and how they may better classify molecular subtypes of MDS. We demonstrated that mutations in several genes are associated with clinical features seen in patients with MDS, potentially explaining much of the heterogeneity associated with this disease. Most importantly, we identified mutations in several genes, that when present, are associated with a poorer prognosis than would otherwise be predicted using standard clinical scoring systems. This has helped accelerate the drive to include tumor sequencing in the standard evaluation of patients with MDS.

    Currently we are investigating how acquired mutations in the diseased cells from patients with myelodysplastic syndromes are associated with their response to treatment with drugs like azacitidine and decitabine. We hope to discover genes that physicians can test for mutations in order to select the best treatment options for their patients with MDS. These studies should also give us insight into the mechanisms of drug resistance and how we may be able to overcome them.

    In addition, we are interested in the functional consequence of the mutations we have characterized in patients with MDS. For example, we are studying how mutations in the EZH2 gene, which are associated with a poor prognosis, might affect the function neutrophils in patients with these abnormalities.

    Going forward, we plan to implement clinical sequencing of bone marrow specimens from patients with MDS and related hematologic malignancies. Our plan is work out how best to use this information to personalize the choice of therapy and overall care of our patients with these disorders.

    Benjamin Ebert, David Steensma, Guillermo Garcia Manero, and their colleagues at the Brigham and Women’s Hospital, the Dana-Farber Cancer Institute, and the MD Anderson Cancer Center – Examination of mutations that may predict response to hypomethylating agents in patients with MDS.
    Nancy Huang and Anjana Rao – La Jolla Institute for Allergy and Immunology – Examination of 5-hydroxymethycytosine in MDS.
    Derek Murphy and Mike Makrigiorgos – Dana-Farber Cancer Institute – High sensitivity methods for detecting rare, but clinically important mutations.

    Education and Training
    MD, PhD - University of California, San Diego, La Jolla, CA - 2003
    Internal Medicine Internship - University of Chicago Hospitals, Chicago, IL - 2003-2004
    Internal Medicine Residency - Brigham and Women's Hospital, Boston, MA - 2004-2006
    Hematology/Oncology Fellowship - Dana Farber Partners Cancer Care, Boston, MA - 2006-2011
    Post-Doctoral Research - Brigham and Women's Hospital, Boston, MA - 2008-2012

    Collapse Research 
    Collapse Research Activities and Funding
    Characterization of Genetic Abnormalities in MDS and Their Clinical Impact
    NIH/NIDDK K08DK091360Apr 2, 2012 - Jun 30, 2012
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. Blood. 2020 Jul 09; 136(2):157-170. Malcovati L, Stevenson K, Papaemmanuil E, Neuberg D, Bejar R, Boultwood J, Bowen DT, Campbell PJ, Ebert BL, Fenaux P, Haferlach T, Heuser M, Jansen JH, Komrokji RS, Maciejewski JP, Walter MJ, Fontenay M, Garcia-Manero G, Graubert TA, Karsan A, Meggendorfer M, Pellagatti A, Sallman DA, Savona MR, Sekeres MA, Steensma DP, Tauro S, Thol F, Vyas P, Van de Loosdrecht AA, Haase D, Tüchler H, Greenberg PL, Ogawa S, Hellstrom-Lindberg E, Cazzola M. PMID: 32347921.
      View in: PubMed   Mentions: 2     Fields:    
    2. Clonal hematopoiesis in cancer. Exp Hematol. 2020 Mar; 83:105-112. Park SJ, Bejar R. PMID: 32044376.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    3. Wide variation in use and interpretation of gene mutation profiling panels among health care providers of patients with myelodysplastic syndromes: results of a large web-based survey. Leuk Lymphoma. 2020 Jun; 61(6):1455-1464. Pine AB, Chokr N, Stahl M, Steensma DP, Sekeres MA, Litzow MR, Luger SM, Stone RM, Greenberg PL, Bejar R, Bewersdorf JP, Gore SD, Zeidan AM. PMID: 32026740.
      View in: PubMed   Mentions:    Fields:    
    4. X-linked macrocytic dyserythropoietic anemia in females with an ALAS2 mutation. J Clin Invest. 2020 Jan 02; 130(1):552. Sankaran VG, Ulirsch JC, Tchaikovskii V, Ludwig LS, Wakabayashi A, Kadirvel S, Lindsley RC, Bejar R, Shi J, Lovitch SB, Bishop DF, Steensma DP. PMID: 31895053.
      View in: PubMed   Mentions:    Fields:    
    5. Hippo kinase loss contributes to del(20q) hematologic malignancies through chronic innate immune activation. Blood. 2019 11 14; 134(20):1730-1744. Stoner SA, Yan M, Liu KTH, Arimoto KI, Shima T, Wang HY, Johnson DT, Bejar R, Jamieson C, Guan KL, Zhang DE. PMID: 31434702.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    6. Advances in Personalized Therapeutic Approaches in Myelodysplastic Syndromes. J Natl Compr Canc Netw. 2019 11; 17(11.5):1444-1447. Bejar R. PMID: 31766023.
      View in: PubMed   Mentions:    Fields:    
    7. DNA methylation identifies genetically and prognostically distinct subtypes of myelodysplastic syndromes. Blood Adv. 2019 10 08; 3(19):2845-2858. Reilly B, Tanaka TN, Diep D, Yeerna H, Tamayo P, Zhang K, Bejar R. PMID: 31582393.
      View in: PubMed   Mentions:    Fields:    
    8. Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial Intelligence. JCO Precis Oncol. 2019; 3. Nazha A, Sekeres MA, Bejar R, Rauh MJ, Othus M, Komrokji RS, Barnard J, Hilton CB, Kerr CM, Steensma DP, DeZern A, Roboz G, Garcia-Manero G, Erba H, Ebert BL, Maciejewski JP. PMID: 31663066.
      View in: PubMed   Mentions:
    9. A pragmatic patient-reported outcome strategy for rare disease clinical trials: application of the EORTC item library to myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. J Patient Rep Outcomes. 2019 Jun 19; 3(1):35. Bell JA, Galaznik A, Pompilus F, Strzok S, Bejar R, Scipione F, Fram RJ, Faller DV, Cano S, Marquis P. PMID: 31218454.
      View in: PubMed   Mentions:
    10. The National MDS Natural History Study: design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromes. Leuk Lymphoma. 2019 12; 60(13):3161-3171. Sekeres MA, Gore SD, Stablein DM, DiFronzo N, Abel GA, DeZern AE, Troy JD, Rollison DE, Thomas JW, Waclawiw MA, Liu JJ, Al Baghdadi T, Walter MJ, Bejar R, Gorak EJ, Starczynowski DT, Foran JM, Cerhan JR, Moscinski LC, Komrokji RS, Deeg HJ, Epling-Burnette PK. PMID: 31111762.
      View in: PubMed   Mentions:    Fields:    
    11. Aging Human Hematopoietic Stem Cells Manifest Profound Epigenetic Reprogramming of Enhancers That May Predispose to Leukemia. Cancer Discov. 2019 08; 9(8):1080-1101. Adelman ER, Huang HT, Roisman A, Olsson A, Colaprico A, Qin T, Lindsley RC, Bejar R, Salomonis N, Grimes HL, Figueroa ME. PMID: 31085557.
      View in: PubMed   Mentions: 4     Fields:    
    12. Myelodysplastic syndrome-associated spliceosome gene mutations enhance innate immune signaling. Haematologica. 2019 09; 104(9):e388-e392. Pollyea DA, Harris C, Rabe JL, Hedin BR, De Arras L, Katz S, Wheeler E, Bejar R, Walter MJ, Jordan CT, Pietras EM, Alper S. PMID: 30846499.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    13. MDS overlap disorders and diagnostic boundaries. Blood. 2019 03 07; 133(10):1086-1095. Tanaka TN, Bejar R. PMID: 30670443.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    14. TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. Leukemia. 2019 07; 33(7):1747-1758. Haase D, Stevenson KE, Neuberg D, Maciejewski JP, Nazha A, Sekeres MA, Ebert BL, Garcia-Manero G, Haferlach C, Haferlach T, Kern W, Ogawa S, Nagata Y, Yoshida K, Graubert TA, Walter MJ, List AF, Komrokji RS, Padron E, Sallman D, Papaemmanuil E, Campbell PJ, Savona MR, Seegmiller A, Adès L, Fenaux P, Shih LY, Bowen D, Groves MJ, Tauro S, Fontenay M, Kosmider O, Bar-Natan M, Steensma D, Stone R, Heuser M, Thol F, Cazzola M, Malcovati L, Karsan A, Ganster C, Hellström-Lindberg E, Boultwood J, Pellagatti A, Santini V, Quek L, Vyas P, Tüchler H, Greenberg PL, Bejar R. PMID: 30635634.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    15. Comprehensive Genomic Profiling Reveals Diverse but Actionable Molecular Portfolios across Hematologic Malignancies: Implications for Next Generation Clinical Trials. Cancers (Basel). 2018 Dec 21; 11(1). Galanina N, Bejar R, Choi M, Goodman A, Wieduwilt M, Mulroney C, Kim L, Yeerna H, Tamayo P, Vergilio JA, Mughal TI, Miller V, Jamieson C, Kurzrock R. PMID: 30583461.
      View in: PubMed   Mentions:
    16. Managing Clonal Hematopoiesis in Patients With Solid Tumors. J Clin Oncol. 2019 01 01; 37(1):7-11. Bolton KL, Gillis NK, Coombs CC, Takahashi K, Zehir A, Bejar R, Garcia-Manero G, Futreal A, Jensen BC, Diaz LA, Gupta D, Mantha S, Klimek V, Papaemmanuil E, Levine R, Padron E. PMID: 30403571.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    17. What biologic factors predict for transformation to AML? Best Pract Res Clin Haematol. 2018 12; 31(4):341-345. Bejar R. PMID: 30466744.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    18. JAK2 double minutes with resultant simultaneous amplification of JAK2 and CD274 in a therapy-related myelodysplastic syndrome evolving into an acute myeloid leukaemia. Br J Haematol. 2019 05; 185(3):566-570. Wang HY, Dell'Aquila ML, Dvanajscak Z, Bejar R, Broome HE, Hsi E, Murray SS, Thorson JA. PMID: 30132795.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    19. Clonal Hematopoiesis in Aging. Curr Stem Cell Rep. 2018 Sep; 4(3):209-219. Park SJ, Bejar R. PMID: 30854305.
      View in: PubMed   Mentions:
    20. The Emerging Potential for Network Analysis to Inform Precision Cancer Medicine. J Mol Biol. 2018 09 14; 430(18 Pt A):2875-2899. Ozturk K, Dow M, Carlin DE, Bejar R, Carter H. PMID: 29908887.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    21. Germ line tissues for optimal detection of somatic variants in myelodysplastic syndromes. Blood. 2018 05 24; 131(21):2402-2405. Padron E, Ball MC, Teer JK, Painter JS, Yoder SJ, Zhang C, Zhang L, Moscinski LC, Rollison DE, Gore SD, Bejar R, Walter MJ, Sekeres MA, Komrokji RS, Epling-Burnette PK. PMID: 29661788.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    22. Molecular Data and the IPSS-R: How Mutational Burden Can Affect Prognostication in MDS. Curr Hematol Malig Rep. 2017 10; 12(5):461-467. Nazha A, Bejar R. PMID: 28844082.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    23. SOHO State of the Art Update and Next Questions: Biology and Treatment of Myelodysplastic Syndromes. Clin Lymphoma Myeloma Leuk. 2017 10; 17(10):613-620. Sallman DA, Tanaka TN, List A, Bejar R. PMID: 29025689.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    24. Implications of molecular genetic diversity in myelodysplastic syndromes. Curr Opin Hematol. 2017 03; 24(2):73-78. Bejar R. PMID: 27875374.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    25. New Insight Into the Biology, Risk Stratification, and Targeted Treatment of Myelodysplastic Syndromes. Am Soc Clin Oncol Educ Book. 2017; 37:480-494. Haider M, Duncavage EJ, Afaneh KF, Bejar R, List AF. PMID: 28561687.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    26. The Impact of Somatic and Germline Mutations in Myelodysplastic Syndromes and Related Disorders. J Natl Compr Canc Netw. 2017 01; 15(1):131-135. Bejar R, Greenberg PL. PMID: 28040723.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    27. Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 01; 15(1):60-87. Greenberg PL, Stone RM, Al-Kali A, Barta SK, Bejar R, Bennett JM, Carraway H, De Castro CM, Deeg HJ, DeZern AE, Fathi AT, Frankfurt O, Gaensler K, Garcia-Manero G, Griffiths EA, Head D, Horsfall R, Johnson RA, Juckett M, Klimek VM, Komrokji R, Kujawski LA, Maness LJ, O'Donnell MR, Pollyea DA, Shami PJ, Stein BL, Walker AR, Westervelt P, Zeidan A, Shead DA, Smith C. PMID: 28040720.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    28. Computational drug treatment simulations on projections of dysregulated protein networks derived from the myelodysplastic mutanome match clinical response in patients. Leuk Res. 2017 01; 52:1-7. Drusbosky L, Medina C, Martuscello R, Hawkins KE, Chang M, Lamba JK, Vali S, Kumar A, Singh NK, Abbasi T, Sekeres MA, Mallo M, Sole F, Bejar R, Cogle CR. PMID: 27855285.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    29. Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study. BMC Cancer. 2016 08 19; 16:652. Steensma DP, Abedi M, Bejar R, Cogle CR, Foucar K, Garcia-Manero G, George TI, Grinblatt D, Komrokji R, Ma X, Maciejewski J, Pollyea DA, Savona MR, Scott B, Sekeres MA, Thompson MA, Swern AS, Nifenecker M, Sugrue MM, Erba H. PMID: 27538433.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    30. Distinct splicing signatures affect converged pathways in myelodysplastic syndrome patients carrying mutations in different splicing regulators. RNA. 2016 10; 22(10):1535-49. Qiu J, Zhou B, Thol F, Zhou Y, Chen L, Shao C, DeBoever C, Hou J, Li H, Chaturvedi A, Ganser A, Bejar R, Zhang DE, Fu XD, Heuser M. PMID: 27492256.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    31. Splicing Factor Mutations in Cancer. Adv Exp Med Biol. 2016; 907:215-28. Bejar R. PMID: 27256388.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    32. DMSO Increases Mutation Scanning Detection Sensitivity of High-Resolution Melting in Clinical Samples. Clin Chem. 2015 Nov; 61(11):1354-62. Song C, Castellanos-Rizaldos E, Bejar R, Ebert BL, Makrigiorgos GM. PMID: 26432802.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    33. MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance. Blood. 2015 Nov 19; 126(21):2355-61. Kwok B, Hall JM, Witte JS, Xu Y, Reddy P, Lin K, Flamholz R, Dabbas B, Yung A, Al-Hafidh J, Balmert E, Vaupel C, El Hader C, McGinniss MJ, Nahas SA, Kines J, Bejar R. PMID: 26429975.
      View in: PubMed   Mentions: 48     Fields:    Translation:Humans
    34. Myelodysplastic Syndromes Diagnosis: What Is the Role of Molecular Testing? Curr Hematol Malig Rep. 2015 Sep; 10(3):282-91. Bejar R. PMID: 26126599.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    35. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015 Jul 02; 126(1):9-16. Steensma DP, Bejar R, Jaiswal S, Lindsley RC, Sekeres MA, Hasserjian RP, Ebert BL. PMID: 25931582.
      View in: PubMed   Mentions: 213     Fields:    Translation:Humans
    36. Myelodysplastic syndromes, version 2.2015. J Natl Compr Canc Netw. 2015 Mar; 13(3):261-72. Greenberg PL, Stone RM, Bejar R, Bennett JM, Bloomfield CD, Borate U, De Castro CM, Deeg HJ, DeZern AE, Fathi AT, Frankfurt O, Gaensler K, Garcia-Manero G, Griffiths EA, Head D, Klimek V, Komrokji R, Kujawski LA, Maness LJ, O'Donnell MR, Pollyea DA, Scott B, Shami PJ, Stein BL, Westervelt P, Wheeler B, Shead DA, Smith C. PMID: 25736003.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    37. X-linked macrocytic dyserythropoietic anemia in females with an ALAS2 mutation. J Clin Invest. 2015 Apr; 125(4):1665-9. Sankaran VG, Ulirsch JC, Tchaikovskii V, Ludwig LS, Wakabayashi A, Kadirvel S, Lindsley RC, Bejar R, Shi J, Lovitch SB, Bishop DF, Steensma DP. PMID: 25705881.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    38. Recent developments in myelodysplastic syndromes. Blood. 2014 Oct 30; 124(18):2793-803. Bejar R, Steensma DP. PMID: 25237199.
      View in: PubMed   Mentions: 46     Fields:    Translation:Humans
    39. Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS. Cancer Cell. 2014 Oct 13; 26(4):509-20. Schneider RK, Ademà V, Heckl D, Järås M, Mallo M, Lord AM, Chu LP, McConkey ME, Kramann R, Mullally A, Bejar R, Solé F, Ebert BL. PMID: 25242043.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansAnimalsCells
    40. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood. 2014 Oct 23; 124(17):2705-12. Bejar R, Lord A, Stevenson K, Bar-Natan M, Pérez-Ladaga A, Zaneveld J, Wang H, Caughey B, Stojanov P, Getz G, Garcia-Manero G, Kantarjian H, Chen R, Stone RM, Neuberg D, Steensma DP, Ebert BL. PMID: 25224413.
      View in: PubMed   Mentions: 128     Fields:    Translation:HumansAnimalsCells
    41. Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. J Clin Oncol. 2014 Sep 01; 32(25):2691-8. Bejar R, Stevenson KE, Caughey B, Lindsley RC, Mar BG, Stojanov P, Getz G, Steensma DP, Ritz J, Soiffer R, Antin JH, Alyea E, Armand P, Ho V, Koreth J, Neuberg D, Cutler CS, Ebert BL. PMID: 25092778.
      View in: PubMed   Mentions: 88     Fields:    Translation:Humans
    42. Clinical and genetic predictors of prognosis in myelodysplastic syndromes. Haematologica. 2014 Jun; 99(6):956-64. Bejar R. PMID: 24881041.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    43. What lies beyond del(5q) in myelodysplastic syndrome? Haematologica. 2013 Dec; 98(12):1819-21. Adema V, Bejar R. PMID: 24323981.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    44. The importance of subclonal genetic events in MDS. Blood. 2013 Nov 21; 122(22):3550-1. Bejar R, Abdel-Wahab O. PMID: 24263953.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    45. Prognostic models in myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program. 2013; 2013:504-10. Bejar R. PMID: 24319225.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    46. Myelodysplastic syndromes: recent advancements in risk stratification and unmet therapeutic challenges. Am Soc Clin Oncol Educ Book. 2013. Bejar R, Tiu RV, Sekeres MA, Komrokji RS. PMID: 23714517.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    47. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol. 2012 Sep 20; 30(27):3376-82. Bejar R, Stevenson KE, Caughey BA, Abdel-Wahab O, Steensma DP, Galili N, Raza A, Kantarjian H, Levine RL, Neuberg D, Garcia-Manero G, Ebert BL. PMID: 22869879.
      View in: PubMed   Mentions: 132     Fields:    Translation:Humans
    48. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011 Jun 30; 364(26):2496-506. Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, Kantarjian H, Raza A, Levine RL, Neuberg D, Ebert BL. PMID: 21714648.
      View in: PubMed   Mentions: 405     Fields:    Translation:HumansCells
    49. Unraveling the molecular pathophysiology of myelodysplastic syndromes. J Clin Oncol. 2011 Feb 10; 29(5):504-15. Bejar R, Levine R, Ebert BL. PMID: 21220588.
      View in: PubMed   Mentions: 89     Fields:    Translation:Humans
    50. The genetic basis of myelodysplastic syndromes. Hematol Oncol Clin North Am. 2010 Apr; 24(2):295-315. Bejar R, Ebert BL. PMID: 20359627.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    51. Transgenic calmodulin-dependent protein kinase II activation: dose-dependent effects on synaptic plasticity, learning, and memory. J Neurosci. 2002 Jul 01; 22(13):5719-26. Bejar R, Yasuda R, Krugers H, Hood K, Mayford M. PMID: 12097524.
      View in: PubMed   Mentions: 24     Fields:    Translation:AnimalsCells
    52. Carotid artery reconstruction following neonatal extracorporeal membrane oxygenation. J Pediatr Surg. 1991 Jul; 26(7):794-9. Moulton SL, Lynch FP, Cornish JD, Bejar RF, Simko AJ, Krous HF. PMID: 1895187.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    53. Neonatal schizencephaly: comparison of brain imaging. Pediatr Neurol. 1990 Nov-Dec; 6(6):382-7. Chamberlain MC, Press GA, Bejar RF. PMID: 2127354.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    54. Cerebral gigantism: concentrations of amino acids in plasma and muscle. J Pediatr. 1970 Jan; 76(1):105-11. Bejar RL, Smith GF, Park S, Spellacy WN, Wolfson SL, Nyhan WL. PMID: 4312004.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    Rafael's Networks
    Concepts (230)
    Derived automatically from this person's publications.
    _
    Co-Authors (21)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _